Copper
Stage IV Pancreatic Cancer AJCC v8
Mayo ClinicPhase 1Dormant
CC
42/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 27/ 100
- Competitive Position
- 89/ 100
Competitive context
14 Active assets in the Stage IV Pancreatic Cancer AJCC v8 cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Cyclophosphamide TME Pharma AG | Phase 3 | BB |
Niraparib OHSU Knight Cancer Institute | Phase 2 | BB |
Dostarlimab University of Washington | Phase 2 | BB |
Palbociclib National Cancer Institute (NCI) | Phase 2 | BB |
Hydroxychloroquine N.N. Petrov National Medical Research Center of Oncology | Phase 2 | B |
View all 19 →
Same molecule, other indications
Copper is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →